Related Experiment Video
Updated: Oct 19, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Primary thromboprophylaxis to prevent thrombotic events in pediatric oncology patients with a malignant mediastinal
Susmita N Sarangi1, Marian Gaballah2, Deirdre Nolfi-Donegan1
1Department of Pediatrics, Zucker School of Medicine at Hofstra Northwell School of Medicine, Division of Hematology Oncology and Cellular Therapy, Steven and Alexandra Cohen Children's Medical Center, New York, New York, USA.
Abstract:
Children with malignant mediastinal masses have increased thrombotic events (TE). Eligible subjects with malignant mediastinal masses between January 2000 and December 2017 were evaluated for TE, with 19 among 76 subjects receiving enoxaparin thromboprophylaxis. There were 13 TEs among 76 subjects for an incidence of 17.1%. Mediastinal compression directly led to TE in 9.2% of subjects who also had statistically significant superior vena cava compression at diagnosis. Primary thromboprophylaxis did not significantly affect TE occurrence; however, larger studies are warranted to consider strategic thromboprophylaxis guided by radiological monitoring of dynamic vascular compression to improve TE outcomes.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pulmonary Embolism III: Nursing Management
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

